Table 6 Comparison of published research and SLV-PSP priorities
Rank | Priority | Number | Percentage |
|---|---|---|---|
1 | Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised? | 34 | 8.0 |
2 | What is the cause of AMD? | 96 | 22.7 |
3 | How can AMD be prevented? | 2 | 0.5 |
4 | Are there ways of restoring sight loss for people with AMD? | 1 | 0.2 |
5 | Can the development of AMD be predicted? | 19 | 4.5 |
6 | What is the most effective way to detect and monitor the progression of early AMD? | 54 | 12.8 |
7 | What factors influence the progression of AMD? | 1 | 0.2 |
8 | Can a non-invasive therapy be developed for wet AMD? | 11 | 2.6 |
9 | Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes prevent or slow the progression of AMD? | 23 | 5.4 |
10 | What are the best enablement strategies for people with AMD? | 11 | 2.6 |
Articles that do not match any of the JLA priorities. Most were concerned with wet AMD | 144 | 34.0 | |
Uncertain | 1 | 0.2 | |
Stargardt’s dystrophy—the SLV-PSP list was only for AMD | 26 | 6.1 |